Empirical anidulafungin therapy increases the treatment efficacy in invasive candidiasis: ERA study results (EraxisR in the Russian Federation)

The objective of the study was to evaluate the effectiveness of empirical therapy with anidulafungin in patients with invasive candidiasis in real clinical practice in Russian healthcare institutions. Materials and methods. In a prospective multicenter (n = 23) ERA study in 2015–2017, 92 adult patients with invasive candidiasis were included. Depending on the type of anidulafungin administration, patients were divided into 2 comparable demographic groups. In the 1st group (n = 52; median age 50.5 ± 13.9 years (19–75 years); men ‒ 62 %), invasive candidiasis was microbiologically confirmed after the initiation of empirical anidulafungin therapy. In the 2nd group (n = 40; median age 47.15 ± 18.01 years (18–98 years); men — 65 %), patients received anidulafungin only after microbiological confirmation of invasive candidiasis. The groups did not statistically differ in risk factors, etiology of invasive candidiasis, the frequency of various organs damage, and also in APACHE II and SOFA score at the time of anidulafungin administration. Results and conclusion. Overall survival on the 30th day after laboratory confirmation of invasive candidiasis was statistically significantly higher in the empirical therapy group (66 % vs 58 %; p = 0.04 416). In addition, the empirical anidulafungin therapy was lead to a significant decrease in the duration of stay in intensive care units (13.5 ± 19.7 days vs 21 ± 15 days) and the total treatment time (22 ± 18 days vs 29 ± 21 days).